2 active not recruiting, 2 withdrawn. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Active not recruiting 2, Withdrawn 2 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib in High-grade Endometrial Cancer Trial Niraparib oral capsule - Endometrial Cancer, Serous Adenocarcinoma | Early Phase 1 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2024-05-01 | 2024-12-19 | |
| Niraparib In Recurrent IDH 1/2 Gliomas Niraparib, Resection/Treatment with Niraparib - Low-grade Glioma, IDH2 Gene Mutation | Early Phase 1 | Active not recruiting | Massachusetts General Hospital | 16 | 2023-05-18 | 2026-07-24 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Niraparib, Radiation therapy - Glioblastoma, Glioblastoma Multiforme | Early Phase 1 | Active not recruiting | Nader Sanai | 42 | 2021-10-29 | 2026-03-09 |
Glioma (2) · Breast Neoplasms (1) · Cystadenocarcinoma, Serous (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1) · Uterine Neoplasms (1)
Massachusetts General Hospital (1) · Nader Sanai (1) · OHSU Knight Cancer Institute (1) · Sir Mortimer B. Davis - Jewish General Hospital (1)
United States (2)
Isabel Arrillaga-Romany, MD, Phd (1) · Lara Davis (1) · Nader Sanai, MD (1) · Shannon Salvador, MD MSc (1) · Walter Gotlieb, MD PhD (1)